证券代码：688621 证券简称：阳光诺和 公告编号：2025-054 北京阳光诺和药物研究股份有限公司 关于变更募集资金专项账户用途、新增募集资金专项 账户并签订三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意北京阳光诺和药物研究股份有限公司 首次公开发行股票注册的批复》（证监许可【2021】1629 号），同意公司首次 公开发行股票的注册申请，北京阳光诺和药物研究股份有限公司（以下简称"公 司"或"阳光诺和"）获准向社会公开发行人民币普通股 20,000,000 股。每股面 值为 1 元，每股发行价格为 26.89 元，本次发行募集资金总额 53,780.00 万元， 减除发行费用 7,061.85 万元（相关费用均为不含税金额），本次公司公开发行新 股的募集资金净额 46,718.15 万元。大华会计师事务所（特殊普通合伙）对公司 本次公开发行新股的资金到位情况进行了审验，并于 2021 年 6 月 17 日出具了《验 资报告》（大华验字[2 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2025-056 北京阳光诺和药物研究股份有限公司 第二届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京阳光诺和药物研究股份有限公司（以下简称"公司"或"上市公司"）于 2025年6月17日召开第二届董事会第二十一次会议。本次会议通知于2025年6月13 日以直接送达、传真与邮件方式发出，会议由董事长利虔先生召集和主持，会议 应出席董事9名，实际出席董事9名，会议的召集和召开符合《中华人民共和国公 司法》（以下简称"《公司法》"）及《北京阳光诺和药物研究股份有限公司章程》 （以下简称"《公司章程》"）等法律、行政法规、部门规章、规范性文件的规定。 二、董事会会议审议情况 经与会董事认真审议，一致通过如下决议： 行股份有限公司北京分行新设募集资金专项账户，该专项账户仅用于"多肽分子 大模型平台项目"等募集资金投向项目募集资金的存储和使用；同意公司全资子 公司北京诺和德美医药技术有限公司在中国民生银行股份有限公司北 ...

Group 1 - The board of directors of Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. convened a meeting to discuss and approve changes to the use of special fundraising accounts and the establishment of new accounts [1][2] - The company agreed to change the purpose of existing fundraising accounts from various research projects to focus on "large model platform projects for peptide molecules" and "innovative drug research projects" [1][2] - New special fundraising accounts will be established by the company's subsidiaries for specific projects, ensuring that the funds are used solely for their intended purposes [1][2] Group 2 - The board approved an adjustment to the grant price of the 2025 restricted stock incentive plan from 22.78 yuan per share to 22.62 yuan per share due to the company's annual equity distribution [2][3] - This adjustment complies with relevant regulations and does not harm the interests of the company or its shareholders [2][3] - The voting results for the incentive plan adjustment showed unanimous support from the board members present [4]

北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号国际企业大厦 A 座 509 单元 邮编：100033 北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 2025 年限制性股票激 励计划调整授予价格事项的 法律意见 京天股字（2025）第 153-3 号 致：北京阳光诺和药物研究股份有限公司 北京市天元律师事务所（以下简称本所）接受北京阳光诺和药物研究股份有 限公司（以下简称公司或阳光诺和）的委托，担任公司 2025 年限制性股票激励 计划（以下简称本激励计划）的专项中国法律顾问并出具法律意见。 本所及经办律师依据《中华人民共和国公司法》 （以下简称《公司法》）、 《中 华人民共和国证券法》 （以下简称《证券法》）、 《律师事务所从事证券法律业务管 理办法》《上市公司股权激励管理办法》（以下简称《管理办法》）、《上海证券交 易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权激励 信息披露》等法律、法规和中国证券监督管理委员会（以下简称中国证监会）的 有关规定及本法律意见出具日以前已经发生或者存在的事实，按照 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 调整公司 2025 年限制性股票激励计划授予价格：22.78 元/股调整为 22.62 元 /股 证券代码：688621 证券简称：阳光诺和 公告编号：2025-055 北京阳光诺和药物研究股份有限公司 关于调整公司 2025 年限制性股票激励计划授予价格 的公告 北京阳光诺和药物研究股份有限公司（以下简称"公司"或"阳光诺和"）于 第六次会议审议通过了《关于调整公司 2025 年限制性股票激励计划授予价格的 议案》等议案。鉴于公司已于 2025 年 6 月 11 日实施完毕 2024 年年度权益分派， 根据《2025 年限制性股票激励计划（草案）》（以下简称"《激励计划（草案）》"） 的规定及公司 2025 年第二次临时股东会的授权，对公司 2025 年限制性股票激励 计划（以下简称"本次激励计划"或"激励计划"）的 2025 年限制性股票激励计划 授予价格进行调整。授予价格（含预留部分）由 22.78 元/股调整为 22.62 元/股。 现将有关事项说 ...

Summary of Key Points Core Viewpoint The company, Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd., has announced changes to the use of raised funds, including the establishment of new special accounts for fundraising and the signing of tripartite supervision agreements to ensure proper management and allocation of these funds. Group 1: Fundraising Overview - The company was approved to publicly issue 20,000,000 shares at a price of 26.89 RMB per share, raising a total of 537.8 million RMB, with a net amount of 467.1815 million RMB after deducting issuance costs [1][2] - The funds are managed in special accounts with a tripartite supervision agreement signed with the sponsor and the supervising bank [2][4] Group 2: Changes in Fund Usage - The company has decided to change the use of surplus funds from completed projects to new projects, specifically the "Polypeptide Molecular Large Model Platform Project" and "Innovative Drug R&D Project" [3][4] - The special accounts for the new projects have been established at various banks, including Ningbo Bank and Industrial Bank, to ensure dedicated management of the funds [4][5] Group 3: Tripartite Supervision Agreement - The tripartite supervision agreements were signed with Minsheng Securities and the respective banks to regulate the management of the raised funds and protect investor interests [5][6] - The agreements stipulate that the funds must only be used for the designated projects and cannot be diverted for other purposes [5][6]

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].

北京阳光诺和药物研究股份有限公司 董事会薪酬与考核委员会 关于 2025 年限制性股票激励计划首次授予激励对象名单的 二、本次激励计划首次授予的激励对象均为公司正式在职员工，为公司董 事、高级管理人员、核心技术人员及董事会认为需要激励的其他人员，其中包含 本次激励计划不包括公司独立董事、单独或合计持有上市公司 5%以上股份 的股东、上市公司实际控制人及其配偶、父母、子女。 三、本次激励计划首次授予的激励对象不存在《管理办法》第八条规定的不 得成为激励对象的情形： （一）最近 12 个月内被证券交易所认定为不适当人选； （二）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； 核查意见 （截至首次授予日） 北京阳光诺和药物研究股份有限公司（以下简称"公司"）董事会薪酬与考核 委员会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《上海证券交易所科创板股票上市规则》（以 下简称"《上市规则》"）、《科创板上市公司自律监管指南第 4 号——股权激 励信息披露》（以下简称"《监管指南第 ...

Core Viewpoint - The legal opinion from Beijing Tianyuan Law Firm confirms that Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has complied with all necessary legal procedures for the initial grant of the 2025 restricted stock incentive plan [1][7]. Group 1: Legal Procedures - The initial grant of the incentive plan was approved by the company's board on May 12, 2025, and the relevant proposals were passed [3]. - The proposed incentive objects were publicly announced from May 13 to May 22, 2025, with no objections raised by employees [4]. - The second extraordinary general meeting of shareholders approved the incentive plan on May 28, 2025, and authorized the board to handle all necessary matters related to the grant [5]. Group 2: Grant Date and Conditions - The board determined the grant date for the incentive plan as June 11, 2025, which complies with relevant regulations [5][6]. - The conditions for granting the restricted stock include the absence of disqualifying circumstances as outlined in the management regulations [6]. - The company has verified that the initial grant of restricted stock to eligible incentive objects meets all legal and regulatory requirements [7].

Group 1 - The board of directors of Beijing Sunshine Nuohua Pharmaceutical Research Co., Ltd. held a meeting where all 9 directors attended, complying with relevant laws and regulations [1][2] - The board unanimously approved the proposal for the initial grant of restricted stock under the 2025 Restricted Stock Incentive Plan, with a grant date of June 11, 2025, and a grant price of 22.78 yuan per share for 1,277,428 shares to 127 eligible recipients [1][2] - The board also approved the addition of the "Information Disclosure Postponement and Exemption System" to regulate the company's information disclosure practices, ensuring compliance with various legal and regulatory requirements [2]